Exploring the potential of immunotherapy in early-stage triple-negative breast cancer
Triple-negative breast cancers, which are more frequently diagnosed in younger women, are a subtype of breast tumor characterized by the absence of hormone receptors and HER2 overexpression. As a result, they do not respond to hormone therapy or HER2-targeted treatments. Their prognosis is generally less favorable than that of other breast cancer subtypes.
Triple-negative breast cancers, which lack hormone receptors and HER2 overexpression, are a challenging subtype to treat. Immunotherapy, particularly immune checkpoint inhibitors, has shown promise in improving outcomes for certain stages of this cancer. However, in early-stage triple-negative breast cancer, particularly stage I, chemotherapy is typically the standard of care. Researchers are exploring ways to optimize treatment while minimizing side effects.
The POP-DURVA study, conducted by Dr. Joana Ribeiro at Gustave Roussy, aimed to assess the potential of very early immunotherapy in stage I triple-negative breast cancer patients. The study administered a short course of durvalumab, an anti-PD-L1 immunotherapy, before standard treatment, which could be either surgery or preoperative chemotherapy.
The primary objective was to determine if two immunotherapy injections were sufficient to induce a pathological complete response, meaning no detectable cancer cells remained in the breast tissue and lymph nodes.
Out of 78 patients enrolled, approximately 11% achieved a major pathological response, indicating a significant reduction in tumor burden. One patient had no residual tumor cells after only two durvalumab injections. The study also revealed changes in the tumor microenvironment, including increased mobilization of immune cells, such as tumor-infiltrating lymphocytes and tertiary lymphoid structures.
These findings suggest that immunotherapy can induce profound biological changes within tumors, potentially reshaping the immune environment to promote antitumor immunity.
While the study was not designed to change treatment standards, the results are encouraging. Observing a pathological response after just two immunotherapy injections is particularly promising. Additionally, the study found that greater increases in tumor-infiltrating lymphocytes were associated with lower proportions of residual viable tumor among patients who proceeded directly to surgery after durvalumab.
These findings highlight the potential of immunotherapy to reshape the immune environment and promote antitumor immunity, even in early-stage triple-negative breast cancer. Further research is needed to establish the long-term clinical significance of these observations.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
